SFA-002

SFA-002 is an investigational, orally administered **deuterated short-chain fatty acid small molecule** developed by SFA Therapeutics for plaque psoriasis. The company describes it as a new chemical entity designed for once-daily dosing that modulates the gut-immune axis, increases interleukin-10 activity, expands regulatory T cells, and is associated with reduced interleukin-17, interleukin-23, interferon-gamma, and tumor necrosis factor signaling without intended broad immunosuppression. SFA-002 completed a Phase 1b plaque-psoriasis study and is listed by its developer as advancing into Phase 2; it has not been approved by the FDA or any other regulatory authority. ([sfatherapeutics.com](https://sfatherapeutics.com/))

Other names

SFA002SFA-002SFA 002